June 30th 2025
Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO.
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
View More
GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
View More
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
View More
Proactive Adverse Event Management for HER2+ BTC Treatments
View More
IMU-131 Plus SOC Improves OS Vs SOC Alone in Advanced/Metastatic Gastric or GEJ Cancer
June 28th 2022Results from the phase 2 HERIZON study identified improved overall survival for patients treated with IMU-131 plus standard of care vs standard of care alone in advanced or metastatic gastric or gastroesophageal junction cancer.
Encouraging pCR Reported With Pembrolizumab Plus Chemo for Resectable Gastric, GEJ Adenocarcinoma
April 11th 2022Patients with resectable gastric and gastroesophageal junction adenocarcinoma experienced good pathologic complete response with standard of care chemotherapy and perioperative/adjuvant pembrolizumab.
177Lu-Dotatate Yields Clinically Relevant But Non-Significant OS Benefit for Midgut NETs
February 27th 2022Patients with advanced midgut neuroendocrine tumors experienced a clinically relevant improvement in median overall survival when treated with 177Lu-Dotatate compared with the control of high-dose long-acting octreotide, although the difference was not significant.
First-Line Nivolumab Combos Yield Improved OS Vs Chemo Alone in Esophageal Cancer
February 22nd 2022The CheckMate 648 trial found that using a combination of nivolumab and chemotherapy or nivolumab plus ipilimumab vs chemotherapy alone improved survival in advanced esophageal squamous-cell carcinoma.